The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis
- 1 January 2007
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 120 (2) , 215-220
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- No significant improvement in diagnostic specificity of an anti‐PF4/polyanion immunoassay with use of high heparin confirmatory procedureJournal of Thrombosis and Haemostasis, 2005
- Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?Journal of Laboratory and Clinical Medicine, 2005
- Role of platelet factor 4–heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysisHemodialysis International, 2005
- Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patientsSurgery, 2004
- Anti-Platelet Factor 4/Heparin AntibodiesCirculation, 2003
- High Plasma Levels of Factor VIII and the Risk of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2000
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Vascular access for hemodialysisKidney International, 1999
- Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysisThe Lancet, 1996
- Heparin-induced thrombocytopenia in hemodialysis patientsAmerican Journal of Kidney Diseases, 1996